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Abstract
Background: Flavopiridol is a cyclin-dependent kinase inhibitor in phase II clinical development for treatment of various
forms of cancer. When administered with a pharmacokinetically (PK)-directed dosing schedule, flavopiridol exhibited
striking activity in patients with refractory chronic lymphocytic leukemia. This study aimed to evaluate pharmacogenetic
factors associated with inter-individual variability in pharmacokinetics and outcomes associated with flavopiridol therapy.
Methodology/Principal Findings: Thirty-five patients who received single-agent flavopiridol via the PK-directed schedule
were genotyped for 189 polymorphisms in genes encoding 56 drug metabolizing enzymes and transporters. Genotypes
were evaluated in univariate and multivariate analyses as covariates in a population PK model. Transport of flavopiridol and
its glucuronide metabolite was evaluated in uptake assays in HEK-293 and MDCK-II cells transiently transfected with
SLCO1B1. Polymorphisms in ABCC2, ABCG2, UGT1A1, UGT1A9, and SLCO1B1 were found to significantly correlate with
flavopiridol PK in univariate analysis. Transport assay results indicated both flavopiridol and flavopiridol-glucuronide are
substrates of the SLCO1B1/OATP1B1 transporter. Covariates incorporated into the final population PK model included
bilirubin, SLCO1B1 rs11045819 and ABCC2 rs8187710. Associations were also observed between genotype and response. To
validate these findings, a second set of data with 51 patients was evaluated, and overall trends for associations between PK
and PGx were found to be consistent.
Conclusions/Significance: Polymorphisms in transport genes were found to be associated with flavopiridol disposition and
outcomes. Observed clinical associations with SLCO1B1 were functionally validated indicating for the first time its relevance
as a transporter of flavopiridol and its glucuronide metabolite. A second 51-patient dataset indicated similar trends between
genotype in the SLCO1B1 and other candidate genes, thus providing support for these findings. Further study in larger
patient populations will be necessary to fully characterize and validate the clinical impact of polymorphisms in SLCO1B1 and
other transporter and metabolizing enzyme genes on outcomes from flavopiridol therapy.
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Introduction
Flavopiridol (Alvocidib, NSC 649890), is a serine/threonine
kinase inhibitor that broadly targets cyclin-dependent kinases
(CDKs), including the cyclin 9/cyclin T complex (pTEF-b),
preventing activation of RNA polymerase II [1–2]. Flavopiridol
initiates cell cycle arrest [3],[4] and p53-independent apoptosis
[5–6] through down-regulation of Mcl-1 and X-linked inactivator
of apoptosis (XIAP) [7,8] [9]. These preclinical characteristics
provided the rationale for clinical investigation of flavopiridol in
chronic lymphocytic leukemia (CLL), as advanced CLL is
commonly associated with elevated Mcl-1 and dysfunctional
p53, rendering standard treatments such as alkylating agents,
fludarabine and rituximab ineffective [10].
Single agent flavopiridol administered with 72-, 24- and 1-hour
infusion schedules produced limited activity in hematologic and
solid tumor diseases [11,12,13,14]. Phase I and II studies using
flavopiridol in combination with other agents utilizing the various
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responses in these trials indicated potential synergy of flavopiridol
with chemotherapy [15]. We previously reported overall response
rates of 40–50% in patients with refractory CLL when flavopiridol
was administered as a single agent using a pharmacokinetically
(PK)-directed schedule [16,17]. A phase II registration trial is
underway for unmet need in refractory CLL patients using this
PK-directed schedule.
The activity of the PK-directed schedule in CLL, compared to
that of the previously evaluated schedules, clearly indicted the
importance of flavopiridol PK for clinical activity, and associations
were in fact observed between PK and clinical outcomes, including
response, cytokine release syndrome (CRS) and tumor lysis
syndrome (TLS) [17]. However, a substantial amount of variability
in PK, as well as in response and toxicity, was unexplained by
demographic, patient and disease characteristics. We therefore
sought to determine the role of pharmacogenetic factors in
flavopiridol PK and treatment outcomes within this patient
population.
Flavopiridol elimination occurs via excretion and metabolism
and is known through in vitro studies to be influenced by the multi-
drug resistance protein-2 (MRP2, ABCC2) [18,19] and the breast
cancer resistance protein (BCRP, ABCG2) [20,21,22,23,24],
which contribute to biliary excretion of both parent drug and
glucuronide metabolites. Glucuronide conjugation to the 5- and 7-
hydroxy positions of flavopiridol by uridine diphosphate glucur-
onosyltransferase isoforms 1A1 and 1A9 (UGT1A1 and UGT1A9,
respectively) accounts for the majority of metabolic transformation
of flavopiridol [25,26]. Polymorphic diversity in these and other
genes may influence flavopiridol disposition, activity and toxicity
in a manner similar to irinotecan disposition [27,28]. Limited
polymorphism effects on flavopiridol interactions have been
reported, including a lack of observed effects on clinical PK [29]
and in vitro substrate specificity [30]. Although polymorphisms
were not directly evaluated by Innocenti and colleagues, their
clinical report suggested flavopiridol:metabolite ratio as a possible
predictor of diarrhea with flavopiridol treatment and provided a
rationale for evaluation of a genetic link with UGT isoforms [31].
In this report, we present pharmacogenetic (PGx) data for drug
metabolizing enzymes and transporters (DMET) in a subset of 35
patients treated in a phase I study of a PK-derived 4.5-hour dosing
schedule of single-agent flavopiridol in relapsed CLL. These data
comprise a focused analysis of candidate genes known through in
vitro studies to interact with flavopiridol, as well as a broader
exploratory evaluation of additional DMET genes. The results
indicate a novel link between flavopiridol PK and SLCO1B1, as
well as functional evidence for OATP1B1 (the organic anion
transporting polypeptide 1B1 protein product of SLCO1B1)
transport of flavopiridol and its glucuronide metabolite. Preliminary
analysis of these associations in a second dataset comprising 51
patients provided additional support for the validity of associations
between PK, transporter and UGT1A1 genes and their potential
clinical relevance. Importantly, pharmacogenetic factors explain a
significant portion of inter-patient variability and improves the
accuracy of a developing population PK model for this agent.
Methods
Patients
Ethics Statement. Samples were obtained from patients who
provided informed written consent and were enrolled on clinical
protocol NCI-5746 (NCT00058240, ClinicalTrials.gov). The
sample collection and analyses reported in this study were outlined
in the clinical protocol, as approved by The Ohio State University
Institutional Review Board (IRB) and in accordance with the
principles expressed in the Declaration of Helsinki. Patient
demographics and disease characteristics, as well as clinical
outcomes and PK results, were reported previously [17]. DNA was
obtainable from peripheral blood mononuclear cells (PBMCs) from
35 of the 52 patients on study. Demographics, baseline labs and
disease characteristics for these patients are presented in Table 1.
Pharmacogenetics
Genes known from in vitro studies to specifically affect
flavopiridol disposition include UGT1A1, UGT1A9, ABCC2
and ABCG2. These and an additional set of 52 other genes that
code for metabolic enzymes and transporters commonly involved
in drug disposition were evaluated for the presence of known
polymorphisms by direct sequencing and with a high-throughput
SNPlex assay (Applied Biosystems) [32]. Genomic DNA was
extracted from patient PBMCs and used to sequence promoter
TATA box regions of UGT1A1 and UGT1A9 and specifically to
identify the presence of the UGT1A1*28 and UGT1A9*22
polymorphisms. Primers for UGT promoter sequencing were as
follows: 1A1-forward, 59 – GGAAGTACTTTGCTGTGTTCA-
Table 1. Demographics and baseline labs of patients
included in pharmacogenetic analyses (n=35).
Demographics
Gender
Male
Female
26
9
Mean (Median) Range
Age years 61 (60) 39–84
Weight kg 82 (82) 51.8–120.7
Body Surface Area m
2 1.9 (1.9) 1.54–2.41
Baseline CBC and Labs
Platelets 610
9/L 112 (110) 16–284
White Blood Cells 610
9/L 75 (23) 3–314.5
Hemoglobin mM 10 (10) 5.8–14.8
Albumin g/dL 3.4 (3.3) 2.8–4.7
Protein g/dL 5.6 (5.5) 4.5–7.3
Calcium mg/dL 8.1 (8.2) 5.8–8.9
Chloride mM 102 (102) 91–111
Potassium mM 4.0 (3.9) 3.2–5.0
Magnesium mg/dL 2.1 (2.0) 1.6–2.6
Sodium mM 139 (139) 136–144
Phosphate mg/dL 5.6 (4.5) 2.3–42.8
Alkaline Phosphatase (ALP) U/L 91 (81) 50–245
Alanine Aminotransferase (ALT) U/L 22 (20) 4.5–74
Aspartate Aminotransferase (AST) U/L 57 (33) 16–470
Bilirubin mg/dL 0.73 (0.68) 0.39–1.52
Creatinine mg/dL 1.1 (1.1) 0.7–1.8
Lactate Dehydrogenase (LDH) U/L 534 (289) 146–5603
Uric Acid mg/dL 3.6 (3.2) 0.7–7.3
Blood Urea Nitrogen mg/dL 15 (14) 8–32
Glucose mg/dL 146 (131) 91–271
Carbon Dioxide meq/L 29 (29) 24–36
doi:10.1371/journal.pone.0013792.t001
Flavopiridol Pharmacogenetics
PLoS ONE | www.plosone.org 2 November 2010 | Volume 5 | Issue 11 | e13792CTCAAG; 1A1-reverse, 59 – AAGGGTCCGTCAGCATGACA-
TCAA; 1A9-forward, 59 – CTTAACATTGCAGCACAGGG-
CATGTT; 1A9-reverse, 59 – CGTACTTGTGCTTTCCATTG-
AGCATGGG. All sequence data was deposited in GenBank. To
validate sequence results of the TATA box regions, single
nucleotide polymorphism (SNP) specific primers were used in a
fluorescence/gel-migration assay. Polymorphism-specific primers
were utilized in the SNPlex assay to identify the presence of 189
other SNPs in drug metabolizing enzymes and transporters. A
complete list of the genes and SNPs evaluated was presented
previously [32].
Population Pharmacokinetic Modeling and Validation
A population PK (popPK) model for 50 patients on study was
previously reported [17]. This model served as the starting point to
evaluate SNPs and other covariates for the subset of 35 patients
with PGx data using NONMEM VI (Icon, Hanover, MD). With
first order conditional estimation, a base structural model was built
with proportional and additive residual error considering both
between-subject variability (BSV) and between-occasion variability
(BOV) on PK parameters, since PK data was available on two
occasions from patients who received escalated doses.
Initial screening of the genetic data was completed with the
allelic association test in HelixTree software (Golden Helix,
Bozeman, MT) which produced unadjusted p-values for correla-
tion with each of the base model-predicted PK parameters. Of the
189 SNPs (191 total including the UGT1A1*28 and UGT1A9*29
promoter polymorphisms from direct sequencing), 16 SNPs in 4
genes known previously to interact with flavopiridol (UGT1A1/9,
ABCC2 and ABCG2), were retained for further analysis. From the
remaining 175 total SNPs in 52 genes that were known to be
involved in drug disposition, we filtered out from consideration
SNPs with p-values.0.05 and minor allele frequencies less than
0.15. For direct fitting of selected polymorphisms to PK
parameters, SNPs were converted to dichotomous categorical
variables whereby the heterozygous category (M/m) for the major
(M) and minor (m) alleles was combined with either the major or
minor allele category as previously reported [33,34].
Demographic, baseline laboratory covariates, and the total of 43
SNPs from above screening were then introduced with general
additive modeling (GAM) and visual inspection of diagnostic plots
using R v.2.9.0 and Xpose 4.0.4. These covariates identified by
visual inspection and GAM as potentially meaningful (according to
the Akaike information criterion, AIC) were introduced into the
population model for further evaluation of the SNP associations.
Using GAM, four sets of covariates including SNPs were retained
for further evaluation in a full structural model.
For completeness, each individual covariate was fit to the
structural model using the power (equation 1) or fractional change
(equation 2) models,
hi~hpop|
CONji
CONj{med
 Hj
|exp(gi) ð1Þ
hi~hpop| 1zCATji|Hj

|exp(gi) ð2Þ
where hi is the individual PK parameter estimate, hpop is the
population parameter estimate for the typical individual, and gi is
the sum of BSV and BOV parameters approximately log-normally
distributed with standard deviations v about a mean of 0. CONji is
the value of the continuous covariate j for individual I, CONj-med is
the population median value of covariate j for all individuals, CATji
is the value of the categorical covariate j for individual i, and Hj is
an estimated parameter. All covariates were evaluated in this way
with the full 50-patient dataset, except for the SNPs which were
evaluated after removal of individuals for whom no genetic data
was available.
To identify a final multivariate model for all of the PK
parameters simultaneously, we used selection methods that depend
on changes in the objective function value. Using a cutoff of
p#.05, which corresponded to a minimum decrease of the
objective function value (OFV) of 3.84 upon inclusion of each
individual covariate based on the likelihood-ratio test, multivariate
analysis with forward stepwise inclusion, backward stepwise
deletion, and forward selection followed by backward elimination
were applied to finalize the covariate model. Model selection in
multivariate analysis was based on 1) minimum reduction of OFV
by 3.84 (P#0.05) for forward inclusion, 2) reduction of OFV by
6.64 or greater (P#0.01) for backward deletion, and 3) decrease in
residual error and/or BSV of the evaluated PK parameter.
Interaction between covariates was examined by scatter plot of
covariate values and change of OFV between models with single
or combined covariates.
For bias evaluation the final model was fitted to replicate datasets
using the bootstrap resampling technique in Wings for NONMEM
[35], and PK parameter estimates and random effects for each of
the replicate datasets were obtained. Two hundred replicate
bootstrap datasets were generated and used for evaluation of
parameter estimate precision. Model precision was evaluated by
comparing mean parameter values and 95% bootstrap confidence
intervals (CI) of the replicates with NONMEM outputs.
Cloning and Expression of SLCO1B1. The human
SLC01B1 gene was isolated from the HEP-G2 cell line using
methods similar to those previously published [36]. Briefly, RNA
was extracted using Trizol Reagent and each half of the gene was
PCR-amplified and cloned into the pcr-blunt II Topo vector
(Invitrogen, Carlsbad, CA). The second half of the gene was
digested with NotI and SnaBI and combined with the first half in
the pcr-blunt II topo vector. The full length clone was then
digested with KpnI and NotI and transferred into pcDNA 3.1 (+)
(Invitrogen). Base pairs that were different from the reference
sequence (NCBI Genbank ID, BC114376) were mutated using
QuickChange (Stratagene, La Jolla, CA) via the manufacturer’s
protocols to match the reference and non-synonymous poly-
morphic variant sequences. Gene orientation and homology of
reference, rs11045819 (T155P), rs2306283 (D130N), and
rs4149056 (V174A) SLCO1B1 SNPs were confirmed through
direct full length sequencing of clones prior to experimentation. A
list of primers used for cloning, sequencing and mutagenesis (for
introduction of nonsynonymous SNPs) is presented in Table 2.
Flavopiridol and Flavo-G Uptake Assays. Flavopiridol was
obtained from the National Cancer Institute Cancer Therapy
Evaluation Program. Flavopiridol-glucuronide (flavo-G) was
extracted from patient urine and purified. Total urine through
24-hours after the start of flavopiridol dosing was collected from
patients enrolled in an IRB-approved phase II protocol (NCI-
7000). Octanol extraction followed by C-18 solid phase extraction
was employed to isolate flavo-G from flavopiridol and other urine
components. To quantify reco-
vered flavo-G and verify purity, samples were incubated with b-
Glucuronidase as previously described [19] and quantified via LC-
MS/MS analysis with methods modified from those previously
reported [37]. Purity was estimated at .95% via mass and UV
chromatography.
Madin-Darby canine kidney (MDCK-II) and human embryonic
kidney (HEK-293) cells, purchased from ATCC (Manassas, VA),
Flavopiridol Pharmacogenetics
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2 at 37uC in Dulbecco’s modified Eagle’s
medium supplemented with L-glutamine, 10% FBS, 100 units/ml
penicillin, and 100 mg/ml streptomycin. Plates (24-well) were
seeded with 2610
5 cells/well and transfected with the reference
and polymorphic OATP1B1-containing vectors using FuGENEH6
Transfection Reagent per the manufacturer’s protocols (Roche).
Transfection efficiency and gene expression were evaluated with
GFP vectors and real-time PCR, respectively. Forty-eight hours
post-transfection, cells were dosed with 10 mM flavopiridol or
flavo-G in OptiMEMH I (Invitrogen, Carlsbad, California)
incubation media containing 4% bovine serum albumin for 10
and 30 minutes, respectively, at 37uC. After incubation, cells were
washed with 4uC versene, trypsinized, and resuspended in 37uC
versene at a total volume of 350 ul. A 150 mL aliquot of the cell
suspension was lysed with 30 ml 6% Triton X-100 in PBS, and
protein concentration was determined using PierceH BCA protein
assay (Thermo Scientific, Rockford, IL). The remaining 200mL cell
suspensions were precipitated with 1mL, 4uC acetonitrile contain-
ing 200nM genistein, followed by vortex mixing and centrifugation
at 16,000g for 10 min. The supernatant (1mL) was removed and
dried in a vacuum concentrator then samples were resuspended in
150mL 95:5 water:acetonitrile plus 0.1% acetic acid, vortexed, and
centrifuged. Supernatants (100 mL) were analyzed using liquid
chromatography and mass spec conditions as described previously
[38]. SN-38 (7-ethyl-10-hydroxycamptothecin, Sigma, St Louis,
MO) and lenalidomide (obtained by extraction from donated
patient capsules as previously reported [39]) were used as positive
and negative control, respectively. Analytical methods for LC-
MS/MS quantification lenalidomide was used as previously
published [38]. For SN-38 LC-MS/MS quantification, a pre-
viously published method was modified and partially validated
[40]. Calculated uptake velocities were normalized to total protein
in each well, and results were compared against empty vector
controls using Student’s t-test.
Evaluation of Associations Between PGx, PK and
Outcomes. To identify associations with genetics, the means
of flavopiridol and flavo-G [17] PK parameters were compared
based on SNP genotypes using Student’s t-test and analysis of
variance (ANOVA). For comparisons of PGx and clinical
outcomes, SNP genotypes and response or toxicity grading was
evaluated using Fisher’s exact test. P-values were not further
adjusted for multiple testing.
Results
Pharmacogenetic Analysis
DNA of adequate quality and quantity for analysis was available
from 35 of the 52 patients treated on study, and both SNPlex and
direct sequencing data were generated for these individuals (see
Table 1 for demographics and pre-treatment characteristics of this
patient subset). In addition to the 4 genes of interest, 17 genes and
27 SNPs met our criteria for further study (see Table 3). Among
these, SLCO1B1 was selected for further evaluation given its
known physiological relevance for a broad set of drugs and its
potential role of transporting flavopiridol into liver for subsequent
metabolism and excretion.
PK Modeling
Base structural model. A total of 577 plasma
concentration-time values from 50 of 52 patients in the clinical
study were included for PK data analysis using two-
compartmental kinetics with first-order elimination, as described
previously [17]. Based on this previous analysis, BSV was initially
assumed on each parameter in the model. However, removal of
BSV for V1 did not significantly change OFV (increase of 1 unit).
After removal of BSV on V1, addition of BOV on single or
multiple parameters was tested in the model. Addition of BOV on
clearance (CL) resulted in the most significant change in OFV.
The final base model thus included BSV on CL, inter-
compartmental clearance (Q) and volume of peripheral
compartment (V2), and BOV on CL. Base model parameter
estimates and random effects are presented in Table 4.
Covariate model. Demographic and lab covariates from
GAM screening were subsequently evaluated in the base model
with univariate analysis (see Table 5). With the modified random
error in the base model, bilirubin was indicated as the most
Table 2. List of primers used for cloning, sequencing, and mutagenesis of SLCO1B1.
Cloning
N-term, Forward (KpnI) 59 GGG GTA CCA TGG ACC AAA ATC AAC ATT TGA AT 39
N-term, Reverse 59 GTT AGC CTT AGA TGA AGG CTG ACC 39
C-term, Forward 59 ACA AGT AAG CAG CTA TAT TGG TGC 39
C-term, Reverse (NotI) 59 GGG CGG CCG CTT AAC AAT GTG TTT CAC TAT CTG 39
Sequencing
N-term, Forward 59 CAT GGA CCA AAA TCA ACA TTT G 39
Middle, Forward 59 GAT TGG TCC AAT CAT TG 39
C-term, Forward 59 GGG AAC CAG TCT GTG G 39
Mutagenesis
rs11045819, Forward 59 CAC TCA ATA GAG CAT CAC CTG AGA TAG TGG G 39
rs11045819, Reverse 59 CCC ACT ATC TCA GGT GAT GCT CTA TTG AGT G 39
rs2306283, Forward 59 GAA ACT AAT ATC AAT TCA TCA GAA AAT TC 39
rs2306283, Reverse 59 GAA TTT TCT GAT GAA TTG ATA TTA GTT TC 39
rs4149056, Forward 59 CAT ACA TGT GGA TAT ATG CGT TCA TGG GTA ATA TGC TTC GT 39
rs4149056, Reverse 59 ACG AAG CAT ATT ACC CAT GAA CGC ATA TAT CCA CAT GTA TG 39
doi:10.1371/journal.pone.0013792.t002
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bilirubin decreased OFV by 8.07 and BSV (on Q) from 63.64% to
55.41% (see Figure 1).
To evaluate genetic covariates, the dataset was reduced by
removing patients for whom no genetic data was available. This
reduced the dataset from 50 to 35 subjects and from 577 to 388
records. Univariate analysis on genetic covariates with this dataset
identified the 14 most significant covariate-parameter relationships
(see Table 6). Using the selection methods discussed above, we
retained in all of the final models SLCO1B1 rs11045819 and
ABCC2 rs8187710. The relationships between these SNPs and
their respective base model-estimated PK parameters are
displayed in Figure 2.
Functional Validation of SCL01B1’s Role in Flavopiridol
and Flavo-G Uptake
Although associations between PK and SNPs in ABCC2 may
have been expected due to known in vitro interactions of MRP2
and flavopiridol, no such evidence existed prior to this study for
the role of SLCO1B1/OATP1B1 in flavopiridol transport. To
determine if the observed associations between flavopiridol PK
and SLCO1B1 PGx were functionally relevant for flavopiridol
disposition, we measured uptake of flavopiridol and flavo-G in
cells transfected with SLCO1B1. Transfection efficiencies were
estimated at approximately 60% using GFP-containing control
vectors. Mean uptake velocities were 261612 fmol/mg protein/
10 min and 38610 fmol/mg protein/30 min for flavopiridol and
flavo-G, respectively, in MDCK-II cells. Flavopiridol transport
rates in HEK-293 cells were approximately 2–3 fold higher than in
MDCK-II cells suggesting its transport may be affected by the
different membrane and transporter compositions in the two cell
lines. Flavo-G transport rates were similar in both cell lines.
Figure 3 shows normalized uptake velocities of flavopiridol and
flavo-G in both HEK293 and MDCK-II cells transfected with
either SLCO1B1 or empty vector. Expression of the transfected
SLCO1B1 gene was verified with real-time PCR (data not shown).
Functional expression of OATP1B1 was verified by evaluating
uptake of a positive control substrate, SN-38 [41]. A second agent,
lenalidomide, was used as a negative control substrate. Total
intracellular accumulation and Initial transport velocities of SN-
38, flavopiridol, and flavo-G were significantly increased in
HEK293 and MDCK-II cells transiently transfected with
Table 3. List of 4 Candidate genes with 16 SNPs and 17
exploratory genes with 27 SNPs having minor allele
frequencies (f).0.15 and allelic association test p,0.05.
Original 16 Candidates Exploratory (f.0.15, p,0.05)
Name ID Name ID
ABCC2 rs17222568 ABCA2 rs2271862
ABCC2 rs2273697 ABCB4 rs1202283
ABCC2 rs3740066 CYP1A2 GID3534
ABCC2 rs717620 CYP1B1 rs1056836
ABCC2 rs8187694 CYP2D6 GID2484
ABCG2 rs1564481 CYP2D6 GID2936
ABCG2 rs2231142 CYP2D6 GID2989
ABCG2 rs2622605 CYP2E1 GID1135
ABCG2 rs2622624 CYP3A4 m392A
ABCG2 rs3114018 CYP3A4 m747C
UGT1A1 *28 (TA)n CYP3A4 GID13989
UGT1A1 1456T.G CYP3A5 31611C
UGT1A1 247T.C CYP3A5 GID6986
UGT1A1 686C.A GSTM3 rs1537234
UGT1A1 rs4148323 GSTM3 rs1799735
UGT1A9 *22 (T)n GSTM3 rs7483
GSTP1 rs4891
GSTP1 rs947894
GSTT1 rs4630
MDR1 GID3435
MTHFR rs1801133
NAT2 GID481
SLCO1B1 rs11045819
SLCO1B1 rs2291075
SLCO1B1 rs4149056
SOD2 rs1799725
SULT1A1 rs1042157
doi:10.1371/journal.pone.0013792.t003
Table 4. Base model PK parameter estimates.
Model Term Parameter Estimate (CV%) BSV (g) (CV%) BOV (CV%)
Full Dataset
CL=hCL?exp(BSVCL+BOVCL) hCL (L/h) 31.6 (4.6) 20.9 (44.9) 22.1 (35.2)
V1=hV1 hV1 (L) 65.4 (2.8)
Q=hQ?exp(BSVQ) hQ (L/h) 8.22 (10.0) 63.6 (27.9)
V2=hV2?exp(BSVV2) hV2 (L) 145 (14.6) 76.6 (34.4)
Reduced Dataset
CL=hCL?exp(BSVCL+BOVCL) hCL (L/h) 30.9 (5.0) 17.0 (71.9) 22.6 (40.4)
V1=hV1 hV1 (L) 64.9 (3.4)
Q=hQ?exp(BSVQ) hQ (L/h) 8.21 (11.6) 57.6 (33.1)
V2=hV2?exp(BSVV2) hV2 (L) 142 (14.6) 67.0 (42.8)
The full (56 subjects, 577 plasma concentrations) and reduced (35 subjects, 388 plasma concentrations) datasets were used. Parameters: CL, clearance; V1, volume of
central compartment; Q, inter-compartmental clearance; V2, volume of peripheral compartment (units are noted in parenthesis). BSV and BOV are listed as %CV. H,
typical value of the PK parameters; BSV, between-subject variability; BOV, between-occasion variability.
doi:10.1371/journal.pone.0013792.t004
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increased uptake was shown for lenalidomide.
We further evaluated the uptake of flavopiridol in MDCK-II cells
transfected with the SLCO1B1 polymorphic variants with amino
acid changes relative to the reference sequence (i.e. nonsynonymous
SNPs). These included rs11045819 (T155P), rs2306283 (D130N),
and rs4149056 (V174A). The results indicated significant decreases
in flavopiridol transport rates (t-test p-value,0.05) for the
rs11045819 and rs4149056 variants, but the transport rate of the
rs2306283 polymorph was similar to that in the reference
SLCO1B1 transporter. Figure 4 displays these results.
Final PK Model Determination
To arrive at a final model with significant PGx, lab and
demographic covariates, the reduced data set was used to
reevaluate the demographic and lab covariates retained after
univariate analysis with the full dataset (see Table 6). Bilirubin
effect on Q was apparent and remained the most significant
demographic or lab covariate with the reduced dataset. However,
significant effects of blood urea nitrogen on CL and alanine
aminotransferase on V2 that were observed in the full dataset
disappeared with use of the reduced dataset. The remaining four
significant demographic or lab covariates and the two significant
SNPs (SLCO1B1 rs11045819 and ABCC2 rs8187710) were then
evaluated by forward addition and backward deletion. Only the
two SNPs and bilirubin were retained as significant covariates with
the reduced dataset. Relative to the base model, the final model
displayed an OFV reduction of 34.11. Table 7 lists the final model
parameter estimates.
The bootstrap method was used to assess bias in the final
covariate model. From the reduced data set, 200 replicate data sets
were generated and used for the evaluation of the stability of the
final covariate model. Table 8 lists the results of the bootstrap
procedure, presented as mean and 95% bootstrap confidence
intervals of the parameter estimates and random effects of the final
model. Mean estimated parameter values from the bootstrap were
within 11% of the parameter estimates of the original data set
indicating reliability in the developed model [42].
Evaluation of Flavo-G and Bilirubin vs. PGx
Flavo-GPKparameter estimatesreported previously in27 ptson
study [17] were evaluated to identify PGx associations. The trends
observed indicatedthat fewer TA repeatsin the UGT1A1 promoter
were weakly associated with lower flavo-G Cmax (2.17+/20.99 vs.
5.08+/24.12 mM) and AUC (26.43+/230.26 vs. 66.16+/
264.37 hr* mM) (p=.057 and .077, respectively). Only two
transporter SNPs were associated with flavo-G PK. The SLCO1B1
rs2306283 SNP correlated with flavo-G plasma concentrations (the
total time in hours flavo-G concentrations were below 1.5 mM,
p=.019), and the ABCG2 rs1564481 SNP was associated with
Table 5. Six significant covariate-parameter correlations after inclusion of single demographic or lab covariates.
Demographic or Lab Covariate Parameter D OFV THETA of Covariate (CV%)
Bilirubin level (BIL) Q 28.07 0.843 (28.6)
Age (AGE) V2 26.348 21.96 (41.3)
Platelet level (PLT) CL 24.925 20.179 (54.3)
White blood cells count (WBC) V1 24.428 20.061 (44,2)
Blood urea nitrogen (BUN) CL 24.34 0.164 (57.2)
Alanine Aminotransferase (ALT) V2 23.878 0.448 (34.4)
Comparison of OFV is made between model with single covariate and the base model. D OFV, change in objective function value.
doi:10.1371/journal.pone.0013792.t005
Figure 1. Individual estimate of Q vs. baseline total bilirubin (with full phase I dataset). Regression analysis; Q=11.21 * Bilirubin
level+0.7422 (P,0.01).
doi:10.1371/journal.pone.0013792.g001
Flavopiridol Pharmacogenetics
PLoS ONE | www.plosone.org 6 November 2010 | Volume 5 | Issue 11 | e13792flavo-G AUC (p=.050). We also evaluated flavopiridol AUC with
respect to PGx, and one trend was observed with the ABCG2
rs2231142 SNP (p=0.08). Bilirubin levels were not associated with
SNPs in UGT1A1, but the SLCO1B1 rs3829310 minor C allele
was associated with higher baseline bilirubin (p=.011). These
relationships are presented in Figure 5.
Correlations of PGx and Outcomes
To determine if the presence of polymorphisms was significantly
associatedwithoutcomes,clinicalresponseandtheprimarytoxicities
(TLS, diarrhea and CRS) were evaluated against PGx. Results
indicated SNPs in SLCO1B1 and ABCG2, but not in UGT1A1/9
or ABCC2, were associated with response. SNPs significantly
associated with improved response included the SCLO1B1
rs11045819 (CC genotype, p=.041) and ABCG2 rs1564481 (T
allele, p=.037). The SLCO1B1 rs2306283 SNP alone did not meet
the significance criteria (T allele, p=.061), but the combination of
this and the SLCO1B1 rs11045819 SNP was significant (p=.007).
No SNPs met the significance criteria when compared against TLS,
although the most closely associated SNP was SLCO1B1 rs4149056
(C allele, p=.056). Similaraly, the most closely associated SNPs with
diarrhea and CRS were SCLO1B1 rs2306283 (T allele, p=.055)
and ABCG2 rs1564481 (T allele, p=.074).
Validation of findings with a Phase II Study
To evaluate the validity of the findings from the 35-patient
dataset, a second dataset was evaluated for associations between
PGx and PK. The validation set comprised data from 66 CLL
patients who were treated with the same flavopiridol dosing
regimen in a separate phase II study (NCI-7000, NCT00098371).
As with the phase I study, enrolled patients provided informed
written consent, and plasma and PBMC samples were obtained
according to The Ohio State University IRB approved protocol.
Clinical results of this study were reported previously [43]. Plasma
and DNA samples from this study were analyzed using the
methods described above to generate flavopiridol and flavo-G
concentration-time data, PK parameter estimates, and PGx data
for each patient. Covariates found to be significantly associated in
univariate analysis with the phase I dataset, including demo-
graphic and baseline laboratory covariates and SNPs in UGT1A1,
ABCC2, ABCG2 and SLCO1B1, were compared with the phase
II pharmacokinetic data.
Significant associations and trends were observed with the
validation dataset. For flavopiridol PK, these included significant
associations between the SCLO1B1 rs2306283 SNP and Q
(p=0.02) and between both the ABCG2 rs2622624 and
rs3114018 SNPs and CL and V1 (rs2622624, p=0.008 and 0.04;
rs3114018, p=0.004 and 0.006 for CL and V1, respectively). The
SLCO1B1 rs3829310 SNP was weakly associated with flavopiridol
CL and AUC (p=0.08 and 0.08, respectively). The ABCG2
rs2231142 SNP showed a similar trend with AUC (p=.08). For
flavo-G, significant associations included Cmax and AUC with the
UGT1A1*28 promotor SNP (p=0.02 and 0.04, respectively).
Bilirubin levels were significantly associated with the SLCO1B1
rs3829310 and SLCO1B1 rs2291075 SNPs (p=0.02 and p=0.04,
respectively). Figure 6 displays a subset of these relationships.
Discussion
Safe and effective use of flavopiridol will require a thorough
understanding of the factors influencing the onset of hyper-acute
tumor lysis syndrome and inter-individual variability in response.
Table 6. Significant covariate-parameter correlations after
inclusion of single genetic covariates.
Genetic Covariate Parameter D OFV
THETA of Covariate
(CV%)
SLCO1B1_rs11045819 V1 218.845 0.426 (35.9)
SLCO1B1_rs4149056 CL 213.144 20.259 (28.3)
ABCC2_rs2273697 V2 212.164 2.27 (66.1)
UGT1A9*22 V1 29.462 0.244 (41.8)
ABCC2_rs8187710 V2 27.542 20.647 (23.3)
UGT1A1*28 CL 25.917 20.224 (55.4)
ABCC2_rs8187710 V1 25.681 20.204 (73.5)
SLCO1B1_rs2291075 V1 25.528 0.191 (51.3)
SLCO1B1_rs2291075 CL 25.28 20.211 (34.4)
ABCC2_rs717620 Q 24.781 0.692 (61.6)
ABCG2_rs3114018 V1 24.721 20.191 (53.4)
SLCO1B1_rs3829310 V1 24.345 20.168 (66.7)
ABCC2_rs717620 CL 24.166 0.201 (58.7)
Comparison of OFV was made between models with single genetic covariates
and the base model, using the reduced dataset with deletion of subjects having
missing values on each individual genetic covariate. D OFV, change in objective
function value.
doi:10.1371/journal.pone.0013792.t006
Figure 2. Relationships between the most significant genetic covariates and estimates for each of the 4 PK parameters from
univariate analysis in the phase I dataset. Box plots represent the scatter of individual V1 estimates vs. SLCO1B1 rs11045819 (Panel A), CL
estimates vs. SLCO1B1 rs4149056 (Panel B), and V2 estimates vs. ABCC2 rs8187710 (Panel C). For rs11045819, data is displayed with V1 estimates
using BSV on V1.
doi:10.1371/journal.pone.0013792.g002
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outcomes may be explained by PK, yet significant portions of this
variability remain unexplained. In this first evaluation of
pharmacogenetics using the flavopiridol PK-derived schedule, we
identified a novel flavopiridol-transporter interaction and con-
firmed its functional relevance in vitro. Furthermore, a subset of the
polymorphisms evaluated in this study was significantly associated
with outcomes. The striking activity of this dosing schedule in CLL
and flavopiridol’s emerging activity with combination chemother-
apy in other diseases demand these pharmacogenetic and other
factors be identified and further characterized.
To expand on our previous evaluation of flavopiridol using the
PK-directed schedule, we sought to characterize the role of PGx in
flavopiridol disposition. We combined focused and exploratory
approaches, whereby PK data from a phase I dataset was
evaluated against SNPs in candidate genes previously shown to
metabolize or transport flavopiridol in in vitro studies, as well as
SNPs in genes not known to interact with flavopiridol. The
candidate genes evaluated included ABCC2, ABCG2, UGT1A1
and UGT1A9. Indeed, at least one SNP in each of these genes was
significantly associated in univariate analysis with flavopiridol and
flavo-G PK. In multivariate analysis with the phase I dataset, a
single SNP in ABCC2 (rs8187710) remained significant. This is a
non-synonymous SNP resulting in a C1515Y alteration and is part
of a haplotype with the rs17222723 SNP (also a non-synonymous
SNP with a V1188E residue change). This haplotype has been
reported to be associated with PBMC accumulation of lopinavir
[44], susceptibility to nonalcoholic fatty liver disease [45], and
doxorubicin-induced cardiotoxicity [46]. This is a relatively
infrequent SNP, and only 5 of 35 and 4 of 51 individuals were
genotyped for the polymorphic A allele in the phase I and II
datasets, respectively. Significant associations between this SNP
and PK parameters were not observed in the phase II dataset.
Although UGT1A1 SNPs were not included in the final popPK
model, both flavopiridol and flavo-G were correlated with the
UGT1A1*28 promoter polymorphism, and fewer TA repeats (6
and 7) were associated with lower flavo-G concentrations and
AUC in both the phase I and II datasets. One of the most broadly
studied substrates of UGT1A1 and 1A9 is irinotecan/SN-38,
which shares metabolic pathways and has a similar toxicity profile
(diarrhea) with flavopiridol. Interestingly, the *3 polymorphism of
1A9 was previously shown to be associated with SN-38 but not
flavopiridol disposition [30]. Innocenti and colleagues measured
ratios of flavo-G:flavopiridol and identified an indirect relationship
between flavo-G levels and diarrhea [31]. Zhai and colleagues
reported PK and UGT1A1 polymorphism data in 49 patients with
refractory neoplasms treated with 1-hour IV flavopiridol [29].
However, their results indicated no correlation of the TATA box
Figure 3. Uptake of flavopiridol, flavo-G, SN-38 and lenalido-
mide in OATP1B1 transfected cells. The bar graph indicates means
+ SD for triplicate determinations of 10 mM flavopiridol, flavo-G, SN-38
and lenalidomide uptake rates in cell lines (HEK-293 or MDCK-II)
transfected with empty control vector or vector cloned with the
OATP1B1 gene (SCLO1B1). Incubations with flavo-G were for 30 min.,
and all other drugs were for 10 min. Transport rates are expressed as
percentages normalized to empty vector control. * p,.05, **
p,0.001,Student’s t-test.
doi:10.1371/journal.pone.0013792.g003
Figure 4. Uptake of flavopiridol in nonsynonymous polymor-
phic variants of OATP1B1. The bar graph indicates means + SD for
triplicate determinations of 10 mM flavopiridol uptake rates in MDCK-II
cells transfected with empty control vector or vector cloned with the
reference or polymorphic SLCO1B1 genes. All incubations were for
10 min. Variants are indicated with respect to their amino acid change;
T155P=rs11045819, D130N=rs2306283, V174A=rs4149056. Transport
rates were normalized to empty vector control. Differences in uptake
rates were compared to the reference OATP1B1 transporter. * p,.05, **
p,0.01, Student’s t-test.
doi:10.1371/journal.pone.0013792.g004
Table 7. Final model parameter estimates.
Parameter Estimate (CV%) BSV (CV%) BOV (CV%)
hCL (L/h) 30.9 (5.6) 17.8 (89.9) 23.3 (44.4)
hV1 (L) 60.6 (4.1)
hQ (L/h) 8.5 (11.5) 57.4 (34.2)
hV2 (L) 181 (15.4) 60.5 (44.0)
hSLCO1B1_rs11045819 (on V1) 0.417 (34.1)
hBIL (on Q) 0.939 (37.2)
hABCC2_rs8187710 (on V2) 20.68 (22.9)
residual error 35.4 (8.2)
The reduced dataset with 35 subjects and 388 plasma concentrations was used.
Parameters: CL, clearance; V1, volume of central compartment; Q,
intercompartmental clearance; V2, volume of peripheral compartment (units
are noted in parenthesis). BSV and BOV are listed as %CV. H, typical value of the
PK parameters; BSV, between-subject variability; BOV, between-occasion
variability.
doi:10.1371/journal.pone.0013792.t007
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severity. While we did not identify correlations with diarrhea for
flavopiridol and flavo-G PK [17], we observed one association
with PGx and diarrhea.
The 35-patient dataset evaluated in this study was small with
regard to exploratory PGx, and therefore an additional dataset
from 51 patients was used to evaluate the validity of the findings.
While the associations identified in each dataset were not identical,
similar trends were observed between PK parameters and SNPs in
the candidate genes. Furthermore, the clinical associations we
observed with SLCO1B1 were functionally validated in vitro.
SLCO1B1 is important for the disposition of statin drugs [47] and
Table 8. Population estimates from final model and bootstrap analysis.
Parameter
Final model estimate
(%CV) Bootstrap summary
Mean Relative bias (%) Lower 95% CI Upper 95% CI
h1 (CL) (L/hr) 30.9 (5.1) 31.30 0.65 27.98 34.62
h2 (V1) (L) 60.6 (4.3) 60.70 20.17 54.60 66.79
h3 (Q) (L/hr) 8.5 (11.5) 8.29 22.59 6.30 10.28
h4 (V2) (L) 181 (15.6) 170.31 24.42 123.31 217.31
h5 (SLCO1B1_rs11045819) (on V1) 0.42 (30.7) 0.44 0.95 0.21 0.67
h6 (BIL) (on Q) 0.94 (36) 0.84 210.96 20.01 1.70
h7 (ABCC2_rs8187710) (on V2) 20.68 (16.5) 20.61 26.18 20.98 20.24
OMEGA1 (CL) 0.18 (64) 0.16 25.23 0.05 0.28
OMEGA2/3 (IOV-CL) 0.23 (34.7) 0.23 1.41 0.15 0.31
OMEGA4 (Q) 0.57 (36.4) 0.52 25.52 0.24 0.80
OMEGA5 (V2) 0.6 (38) 0.56 25.57 0.29 0.84
Relative bias,i(%)=(Pbs,i2Pest,i)/Pest,I6100; Pbs,i: mean of parameter i estimate from bootstrap; Pest,i: final parameter i estimate.
doi:10.1371/journal.pone.0013792.t008
Figure 5. Association of PGx, PK and bilirubin from the phase I dataset. Flavo-G PK parameter estimates from 27 patients were evaluated for
relationships with PGx. Fewer TA repeats in the UGT1A1 promoter were weakly associated with lower flavo-G Cmax (Panel A) and AUC (Panel B). For
SLCO1B1, the rs2306283 SNP correlated with flavo-G plasma concentrations (the total time flavo-G plasma concentrations were below 1.5 mM,
p=.019; Panel C, one outlier removed). For ABCG2, the rs1564481 SNP was associated with flavo-G AUC (p=.050; Panel D) and the rs2231142 SNP
was associated with flavopiridol AUC (p=0.08, Panel E). The SLCO1B1 rs3829310 minor C allele was associated with higher baseline total bilirubin
(p=.011; Panel F). For plots A and B, the x-axis indicates the number of promoter TA repeats for both gene copies (6.7=6 and 7 TA repeats; 7=7 TA
repeats for each gene copy; 7.8=7 and 8 TA repeats; 8=8 TA repeats for each gene copy).
doi:10.1371/journal.pone.0013792.g005
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recently highlighted by the International Transporter Consortium
as one of the seven most relevant transporters for drug
development due to its broad substrate specificity, potential for
drug-drug interactions, and clinically relevant polymorphisms
[49]. Importantly, functional transport data indicated this gene
may play a role in hepatic uptake of both flavopiridol and flavo-G.
All five of the SLCO1B1 SNPs evaluated in the phase I dataset
were significant in univariate analysis, and two of these
(rs11045819 on V1 and rs4149056 on CL) were the strongest
associations observed of any covariates evaluated for flavopiridol
PK in multivariate analysis. These are non-synonymous SNPs
affecting the amino acid sequence in OATP1B1. Previous studies
indicated these variants were associated with reduced uptake
activity of the OATP1B1 substrates estrone-3-sulfate, estradiol-
17b-d-glucuronide, atorvastatin, cerivastatin, pravastatin, the SN-
38 metabolite of irinotecan and rifampicin in [50–51]. These
reports are consistent with our in vitro data which indicated these
SNPs significantly reduced flavopiridol transport, while the other
nonsynonymous SNP evaluated (rs2306283) had no measureable
effect. Interestingly, this was the only SLCO1B1 SNP significantly
associated with flavo-G PK. A recently reported study in MDCK-
II cells with this SNP indicated increased transport of bromo-
sulfophthalein and decreased transport of cholyltaurine [51].
Collectively, the data may suggest that the altered protein
sequence affects OATP1B1 transport of flavopiridol and flavo-G
differently. Further in vitro evaluations of these and other SNPs will
be required to characterize their functional impact with respect to
flavopiridol and flavo-G disposition. Additionally, the data
presented suggests flavopridol may be a weak substrate of
SLCO1B1 in comparison with SN-38 under the evaluated
experimental conditions. However, characterization of the kinetics
of flavopiridol and flavo-G transport via SLCO1B1 will be
necessary for understanding the full impact this gene has on
overall flavopiridol disposition.
The observed associations between PGx and outcomes in this
study are encouraging as potential indicators for patient response.
While no SNP met the significance criteria for association with
TLS, the polymorphism most closely associated with this toxicity
was SLCO1B1 rs4149056 (ANOVA p=.056). The strength of the
associations between PK, outcomes and multiple SNPs in
SLCO1B1 and the confirmation of functional OATP1B1
transport of both flavopiridol and flavo-G support the potential
for this gene to be clinically relevant in patients receiving
flavopiridol treatment. Overall, analysis of the phase II dataset
revealed significant associations with the candidate genes that were
supportive of the findings from the phase I dataset. In particular,
trends in flavopiridol AUC with respect to the ABCG2 rs2231142
SNP and flavo-G Cmax and AUC with respect to the
UGT1A1*28 polymorphism were strikingly similar between the
two datasets (see Figures 5 and 6). Again, further validation of
these associations will be essential in larger datasets.
Figure 6. Association of PGx and PK from the phase II dataset. Flavopiridol and flavo-G PK parameter estimates from the phase II study was
evaluated for relationships with PGx. Presented are flavopiridol CL associations with ABCG2 rs2622624 (p=0.008, Panel A) and rs3114018 (p=0.004,
Panel B); UGT1A1*28 (promoter) polymorphisms associated with flavo-G Cmax (p=0.02, Panel C) and AUC (p=0.04, Panel D); the ABCG2 rs2231142
SNP was weakly associated with flavopiridol AUC (Panel E, p=.08); For plots C and D, the x-axis indicates the number of promoter TA repeats for both
gene copies (6.7=6 and 7 TA repeats; 7=7 TA repeats for each gene copy; 7.8=7 and 8 TA repeats; 8=8 TA repeats for each gene copy).
doi:10.1371/journal.pone.0013792.g006
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reported population model for the PK-directed schedule of
flavopiridol. We demonstrate the most significant covariates in
the phase I dataset to be polymorphisms in two transporter genes,
SCLO1B1 and ABCC2, and the phase II validation set revealed
significant associations with polymorphisms in ABCG2. While
larger data sets are necessary to fully characterize the clinical
impact of polymorphisms in SLCO1B1 and other genes on
flavopiridol PK, our findings are supportive of a clinically
significant role for PGx in flavopiridol disposition. The composite
data to date suggests inter-individual variability in outcomes from
flavopiridol therapy will be due to a combination of pharmaco-
kinetics, pharmacogenetics and potentially other factors related to
tumor cell sensitivity to flavopiridol’s cytotoxic effects. Inter-
individual variability is of particular concern for chemotherapeutic
drugs with relatively narrow therapeutic windows. The developing
model for flavopiridol PK may ultimately help to explain this
variability by incorporating pharmacogenetic and other significant
factors. With sufficient data and validation, this model may
ultimately serve as a tool for predicting PK and associated
outcomes in individuals prior to therapy. If sufficiently robust, such
a tool would be clinically useful in identifying individuals likely to
respond and/or experience severe TLS or other toxicities upon
receiving flavopiridol. As a phase II registration study of
flavopiridol in relapsed CLL nears completion and additional
combination studies in hematologic and solid tumor diseases begin
accruing patients, further exploration and characterization of the
factors influencing inter-individual variability in outcomes from
therapy will be necessary to insure the broad and safe clinical use
of this drug.
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